Evidence map›Paper›PMID 40355435›Full record

ArticleNature communications2025

Structural proteomics defines a sequential priming mechanism for the progesterone receptor.

Matthew D Mann, Min Wang, Josephine C Ferreon, Phoebe S Tsoi, Michael P Suess, Antrix Jain, Anna Malovannaya, Roberto Vera Alvarez, Bruce D Pascal, Raj Kumar and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Matthew D MannSkaggs Graduate School of Chemical and Biological Sciences, Scripps Research, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4474-4592
Min WangDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Josephine C FerreonVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3175-5700
Phoebe S TsoiVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA.
Michael P SuessDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Antrix JainMass Spectrometry Proteomics Core Facility. Advanced Technology Cores, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2815-3645
Anna MalovannayaVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2953-6485
Roberto Vera AlvarezOmics Informatics LLC, Honolulu, HI, USA.
Bruce D PascalOmics Informatics LLC, Honolulu, HI, USA.
Raj KumarDepartment of Pharmaceutical and Biomedical Sciences, Touro College of Pharmacy, Touro University, New York, NY, USA.
Dean P EdwardsDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Patrick R GriffinSkaggs Graduate School of Chemical and Biological Sciences, Scripps Research, La Jolla, CA, USA. pgriffin2@ufl.edu.ORCID http://orcid.org/0000-0002-3404-690X

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
Structural dynamics of progesterone receptor-coactivator complexesR01CA263574 · NCI · UNIVERSITY OF FLORIDA · PI Dean P Edwards, Patrick Robert Griffin · 2022 to 2026
$3.0M
Customized and Integrated Multi-Angle Light Scattering (MALS)-based Multidetection SystemS10OD030276 · OD · BAYLOR COLLEGE OF MEDICINE · PI FERREON, JOSEPHINE CHU · 2022 to 2022
$335k
NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA263574NIH HHS S10 OD030276U.S. Department of Health & Human Services | National Institutes of Health (NIH) CA263574
6 · The paper itself

Abstract

The progesterone receptor (PR) is a steroid-responsive nuclear receptor with two isoforms: PR-A and PR-B. Disruption of PR-A:PR-B signaling is associated with breast cancer through interactions with oncogenic co-regulatory proteins (CoRs). However, molecular details of isoform-specific PR-CoR interactions remain poorly understood. Using structural mass spectrometry, we investigate the sequential binding mechanism of purified full-length PR and intact CoRs, steroid receptor coactivator 3 (SRC3) and p300, as complexes on target DNA. Our findings reveal selective CoR NR-box binding by PR and unique interaction surfaces between PR and CoRs during complex assembly, providing a structural basis for CoR sequential binding on PR. Antagonist-bound PR showed persistent CoR interactions, challenging the classical model of nuclear receptor activation and repression. In this work, we offer a peptide-level perspective on the organization of the PR transcriptional complex and infer the mechanisms behind the interactions of these proteins, both in active and inactive conformations.

Indexed as

ProteomicsReceptors, ProgesteroneDNAFemaleHumansNuclear Receptor Coactivator 3Protein BindingProtein IsoformsDNANCOA3 protein, humanNuclear Receptor Coactivator 3progesterone receptor BProtein IsoformsReceptors, Progesterone

Identifiers

PMID40355435
PMCPMC12069617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.